Apatinib as Second-line Treatment of Advanced Pancreatic Cancer

Inclusion Criteria:

* ≥ 18 and ≤ 70 years of age,Male or female;
* The advanced pancreatic cancer pathology, with measurable lesions (spiral CT scan is more than 10mm, according to the standard of RECIST 1.1);
* Locally advanced, unresectable recurrent or metastatic pancreatic cancer;
* According to CTCAE 4.0 and patient complaints, the researchers determine second-line chemotherapy should not be tolerated by the patients or patients want to receive second-line chemotherapy.
* ECOG performance scale 0-1;
* Baseline blood routine and biochemical indexes meet the following criteria:
* Hemoglobin ≥ 80g/L,
* The absolute neutrophil count (ANC) ≥ 1.5 ×109/L,
* Blood platelet ≥ 90 ×109/L
* Alanine aminotransferase(ALT),Aspartate transaminase (AST) less than 2.5 times the upper limit of normal value, equal to or less than 5 times the upper limit of normal (liver metastasis),
* the serum total bilirubin is less than 1.5 times the upper limit of normal value,
* Serum creatinine. Less than 1.5 times the upper limit of normal value,
* Serum albumin is more than 30g/L;
* Life expectancy ≥ 3 months.
* women of childbearing age to within 7 days before entering the group of serum or urine pregnancy test and the results were negative. And be willing to give drug test during the test and the last 8 weeks using an appropriate method of contraception. For men, for sterilization, or agreed to during the period of the experiment and at the end of the given experimental drugs for 8 weeks by appropriate methods of contraception;
* In this study, volunteer subjects signed the informed consent, good compliance with follow-up.

Exclusion Criteria:

* It is confirmed that of apatinib and / or its accessories allergy;
* Have high blood pressure and antihypertensive drug treatment can not drop to normal range(systolic pressure \>140 mmHg, diastolic blood pressure 90\>mmHg), suffering from coronary artery disease above grade I, grade I arrhythmia (including corrected QT interval prolongation male \> 450 ms, women \> 470 MS) and grade I heart insufficiency; urine protein positive patients.
* Has a variety of factors influencing oral drugs (such as unable to swallow, nausea, vomiting, chronic diarrhea and intestinal obstruction, etc.);
* Coagulant function abnormality (INR\>1.5, activated partial thromboplastin time(APTT)\>1.5, ULN) with bleeding tendency;
* patients with central nervous system metastasis;
* pregnant or lactating women;
* Patients with other malignant tumors within five years;
* Has a history of psychiatric drugs abuse and can't quit or patients with mental disorders;
* 4 weeks participated in other clinical trials of patients;
* received VEGFR inhibitors, such as sorafenib, chougny for treatment;
* According to the researcher's judgment, there is serious to endanger the safety of patients or affect patients with disease to do the research;
* The researchers think that the person doesn't fit into.